3/15/2019 7:03:08 AM
Sutro Biopharma Initiates Phase I Clinical Trial Of STRO-002 For Ovarian And Endometrial Cancers
3/4/2019 6:57:52 AM
Wedbush Reiterates SUTRO BIOPHARMA INC (STRO) At Outperform With $22 Up From $20 Price Target
1/29/2019 7:11:04 AM
Sutro Biopharma Appoints Andreas Maderna VP Of Chemistry
11/13/2018 7:45:38 AM
Sutro Announces IND Submission And Conclusion Of 30-Day Review Period For STRO-002
10/22/2018 6:23:24 AM
Wedbush Initiates SUTRO BIOPHARMA INC (STRO) At Outperform With $20 Price Target
10/12/2018 7:05:40 AM
Sutro Biopharma Says STRO-001 Receives FDA Orphan Drug Designation For Treatment Of Multiple Myeloma